Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years
In the world of GLP-1 medications and peptide therapy for metabolic health, few stories capture innovation's fragile timing like Zydus Lifesciences' ZYOG1. Developed in Mumbai 15 years ago—well before the surge of anti-obesity drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide)—this oral GLP-1 agonist represented a bold leap in diabetes and obesity treatment. ZYOG1's journey underscores the challenges of bringing oral peptides to market, preserving key lessons for patients and researchers today.
What Are GLP-1 Agonists and Why Oral Delivery Matters
GLP-1 agonists, or glucagon-like peptide-1 agonists, mimic the GLP-1 hormone to manage type 2 diabetes and obesity. They work by slowing stomach emptying, reducing food cravings, and promoting insulin secretion in response to meals. Injectable versions like Ozempic and Mounjaro have transformed metabolic health, but oral formulations address a major patient barrier: needles.
Peptides, the short amino acid chains powering GLP-1 drugs, are notoriously fragile. They degrade in the gastrointestinal tract due to stomach acid and enzymes, leading to poor absorption and low efficacy. Scientists worldwide labored to engineer oral delivery, making ZYOG1's development an audacious goal for Zydus, especially when obesity drugs lacked market traction and big pharma focused on anti-diabetes injectables.
ZYOG1's Unique Platform Technology
ZYOG1 was designed using a proprietary platform technology at Zydus Lifesciences, then known as Zydus Cadila. This innovation aimed to protect the peptide from GI breakdown, enabling pill-based therapy akin to modern oral semaglutide (Rybelsus).
Preclinical Success: Glucose Control, Weight Loss, and Safety
In preclinical models, ZYOG1 demonstrated compelling effects: significant reductions in glucose levels and HbA1c, alongside weight loss benefits. Crucially, it showed a differentiated safety profile with no nausea-like symptoms— a common side effect that plagues many GLP-1 agonists and impacts patient adherence.
These results positioned ZYOG1 as a dual-threat for diabetes and emerging obesity needs, mirroring the multi-benefits seen today in drugs like Wegovy and Zepbound.
Milestone: Phase I Trial Approval in 2010
In June 2010, Zydus announced it had received permissions from the Drugs Controller General of India to conduct phase I clinical trials for ZYOG1. This green light validated the drug's early promise and highlighted Zydus' innovative pipeline ambitions.
"This novel molecule would address unmet medical needs in treating diabetes and holds promising potential in the anti-diabetic and anti-obesity market," said Pankaj Patel, chairman of Zydus.
Patel's optimism reflected the scientific backing, including guidance from key advisors.
The Brain Trust: Richard DiMarchi's Expertise
Among ZYOG1's key advisors was Richard DiMarchi, a distinguished professor at Indiana University with deep GLP-1 research credentials. DiMarchi had spent years as a scientist at Eli Lilly, contributing to foundational work in peptide therapies. His involvement lent global credibility to Zydus' efforts, bridging Indian innovation with Western expertise.
Why Zydus Shelved ZYOG1: Costs and Market Realities
Despite the momentum, Zydus shelved ZYOG1's clinical development. A veteran scientist explained to ET: "At that time, research in diabetes drugs involved significant global clinical development costs as the US FDA had laid out stringent safety regulations. Sustaining the costs was difficult and obesity was not even seen as a big unmet opportunity."
